布地奈德联合沙丁胺醇雾化吸入治疗AECOPD的疗效及对肺功能相关指标的影响  

Efficacy of aerosol inhalation of budesonide plus salbutamol in treatment of patients with acute exacerbation of chronic obstructive pulmonary disease and its influence on the related indexes of lung function

作　　者：王沁[1] 宋德胤[1] 

机构地区：[1]江苏省南京市中医院呼吸科,江苏南京210001

出　　处：《实用临床医药杂志》2016年第7期38-40,44,共4页Journal of Clinical Medicine in Practice

基　　金：中国高校医学期刊临床专项资金(11525495)

摘　　要：目的观察布地奈德联合沙丁胺醇雾化吸入治疗慢性阻塞性肺疾病急性加重期(AECOPD)的临床疗效及其对肺功能相关指标的影响。方法选取AECOPD患者324例,随机分为布地奈德单药组、沙丁醇单药组和联合组,每组108例。3组均给予吸氧、抗感染、祛痰、止咳平喘等基本疗法。在此基础上,布地奈德单药组给予布地奈德混悬液;沙丁醇单药组给予硫酸沙丁醇胺;联合组给予布地奈德混悬液+硫酸沙丁醇胺。观察3组治疗后临床疗效和不良反应发生情况,以及治疗前后6 min步行距离(6 MWD)、呼吸困难评分及肺功能指标变化。结果联合组总有效率为95.37%,显著高于2个单药组(P<0.01),但单药组间比较无显著差异(P>0.05)。治疗后,3组呼吸困难评分、6 MWD和肺功能指标均有显著改善(P<0.01),且联合组改善幅度显著高于2个单药组(P<0.05或P<0.01);单药组间比较无显著差异(P>0.05)。3组不良反应发生率比较无显著差异(P>0.05)。结论与单药相比,布地奈德联合沙丁胺醇雾化吸入可有效提高AECOPD患者的临床疗效、症状和肺功能,且不良反应较低,值得临床推广。Objective To observe the clinical efficacy of aerosol inhalation of budesonide plus salbutamol in the treatment of patients with acute exacerbation of chronic obstructive pulmonary disease（ AECOPD） and its influence on the related indexes of lung function. Methods A total of324 patients with AECOPD were randomly divided into budesonide group（ n = 108）,salbutamol group（ n = 108） and combined group（ n = 108）. The patients in three groups were all treated with basic therapies,such as oxygen uptake,anti- infection,phlegm elimination and alleviation of cough and asthma. Based on thses,budesonide group,salbutamol group and combined group were respectively given budesonide suspension,albuterol sulfate and budesonide suspension plus albuterol sulfate. The clinical efficacy and incidence rate of adverse reactions in three groups were observed after treatment,and 6 min walk distance（ 6 MWD）,dyspnea scores as well as the related indexes of lung function were compared before and after treatment. Results The overall response rate in combined group（ 95. 37%） was significantly higher than those in the other two groups（ P〈0. 01）,but there was no significant difference between budesonide group and salbutamol group（ P〈0. 05）. After treatment,all the dyspnea scores,6 MWD and related indexes of lung function in three groups improved significantly（ P〈0. 01）,and the improved degree in combined group was significantly greater than that in the other two groups（ P〈0. 0 5 or P〈0. 0 1）,but there was no significant difference between budesonide group and salbutamol group（ P〈0. 0 5）. There was no significant differencein incidence rate of adverse reactions in three groups（ P〈0. 05）. Conclusion Compared with budesonide or salbutamol alone,aerosol inhalation of budesonide plus salbutamol can effectively improve the clinical efficacy,symptoms and lung function of patients with AECOPD,and it has lower incidence rate of adverse reactions,so it is worthy of popularization.

关 键 词：慢性阻塞性肺疾病 布地奈德 沙丁胺醇 雾化吸入 临床疗效 

分 类 号：R441.8[医药卫生—诊断学]